jrnl1391

Publication Venue For

  • Clinical trials of xenotransplantation: The need for a worldwide registry..  e12598. 2020
  • Recommendations to the IRB review process in preparation of xenotransplantation clinical trials.  27. 2020
  • Fluid intake and output in baboons 2020
  • Meta-analysis of public perception toward xenotransplantation 2020
  • Decellularization methods for developing porcine corneal xenografts and future perspectives.  26. 2019
  • Downregulation of Gabarapl1 significantly attenuates antibody binding to porcine aortic endothelial cells.  26. 2019
  • Selective inhibition of cyclooxygenase-2 protects porcine aortic endothelial cells from human antibody-mediated complement-dependent cytotoxicity.  26. 2019
  • A potential role of TLR2 in xenograft rejection of porcine iliac endothelial cells: An in vitro study.  26. 2019
  • Circulating pig-specific DNA as a novel biomarker for monitoring xenograft rejection.  26. 2019
  • Justification of specific genetic modifications in pigs for clinical organ xenotransplantation.  26. 2019
  • The complex functioning of the complement system in xenotransplantation.  26. 2019
  • The “Baby Fae” baboon heart transplant—Potential cause of rejection.  26. 2019
  • A review of pig liver xenotransplantation: Current problems and recent progress.  26. 2019
  • Carbohydrate antigen expression and anti-pig antibodies in New World capuchin monkeys: Relevance to studies of xenotransplantation.  26. 2019
  • Cover Image, Volume 26, Issue 3.  26. 2019
  • Financial support for xenotransplantation research.  26. 2019
  • Life-supporting porcine cardiac xenotransplantation: The Munich study.  26. 2019
  • Potential pathological role of pro-inflammatory cytokines (IL-6, TNF-α, and IL-17) in xenotransplantation.  26. 2019
  • Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation.  26. 2019
  • Episodes of hypovolemia/dehydration in baboons with pig kidney transplants: A new syndrome of clinical importance?.  26. 2019
  • Oscar Salvatierra, Jr, MD (1935-2019).  26:e12521. 2019
  • Will donor-derived neoplasia be problematic after clinical pig organ or cell xenotransplantation?.  26. 2019
  • Circulating miRNA or circulating DNA—Potential biomarkers for organ transplant rejection.  26. 2019
  • An approach to induction of tolerance to pig cardiac xenografts in neonates.  25. 2018
  • Porcine IL-6, IL-1β, and TNF-α regulate the expression of pro-inflammatory-related genes and tissue factor in human umbilical vein endothelial cells.  25. 2018
  • Donor-derived infections and infectious risk in xenotransplantation and allotransplantation.  25. 2018
  • 20th Anniversary of IXA, 1998–2018.  25. 2018
  • Is sensitization to pig antigens detrimental to subsequent allotransplantation?.  25. 2018
  • Jewish, Christian and Muslim theological perspectives about xenotransplantation.  25. 2018
  • Cover Image, Volume 25, Issue 2.  25:e12397-e12397. 2018
  • The Sda and Cad glycan antigens and their glycosyltransferase, β1,4GalNAcT-II, in xenotransplantation.  25. 2018
  • The Natural Anti-Gal Antibody as Foe Turned Friend in MedicineUri GaliliPhD, Academic Press (an imprint of Elsevier), London, 2018. pp. 1-300. Price US$95.50..  25:e12364-e12364. 2018
  • Low anti-pig antibody levels are key to the success of solid organ xenotransplantation: But is this sufficient?.  24. 2017
  • Miscellaneous.  24. 2017
  • David J. G. White, PhD, FRCPath.  24. 2017
  • Angiopoietin-1 and angiopoietin-2 protect porcine iliac endothelial cells from human antibody-mediated complement-dependent cytotoxicity through phosphatidylinositide 3-kinase/AKT pathway activation.  24. 2017
  • Financial aspects of organ procurement from deceased donors in the USA—Relevance to xenotransplantation.  24. 2017
  • The impact of serum incubation time on IgM/IgG binding to porcine aortic endothelial cells.  24. 2017
  • Early clinical xenotransplantation experiences—An interview with Thomas E. Starzl, MD, PhD.  24. 2017
  • Human IL-6, IL-17, IL-1β, and TNF-α differently regulate the expression of pro-inflammatory related genes, tissue factor, and swine leukocyte antigen class I in porcine aortic endothelial cells.  24. 2017
  • Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts.  24. 2017
  • Therapeutic regulation of systemic inflammation in xenograft recipients.  24. 2017
  • Thomas E. Starzl, MD, PhD, 1926-2017.  24. 2017
  • Transplantation of hepatocytes from genetically engineered pigs into baboons.  24. 2017
  • Development of retrocorneal membrane following pig-to-monkey penetrating keratoplasty.  24. 2017
  • Initial study of α1,3-galactosyltransferase gene-knockout/CD46 pig full-thickness corneal xenografts in rhesus monkeys.  24. 2017
  • Klotho attenuated antibody-mediated porcine endothelial cell activation and injury.  24. 2017
  • Safe use of anti-CD154 monoclonal antibody in pig islet xenotransplantation in monkeys.  24. 2017
  • Human antibody recognition of xenogeneic antigens (NeuGc and Gal) on porcine heart valves: could genetically modified pig heart valves reduce structural valve deterioration?.  23:370-380. 2016
  • Psychosocial challenges of xenotransplantation: the need for a multidisciplinary, religious, and cultural dialogue.  23:335-337. 2016
  • Is successful orthotopic heart transplantation in the pig-to-non-human primate model required before proceeding to a clinical trial?.  23:328-329. 2016
  • Thyroid hormone: relevance to xenotransplantation.  23:293-299. 2016
  • Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs.  23:137-150. 2016
  • The pathobiology of pig-to-primate xenotransplantation: A historical review.  23:83-105. 2016
  • First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Chapter 2b: Genetically modified source pigs.  23:32-37. 2016
  • First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Chapter 4: Pre-clinical efficacy and complication data required to justify a clinical trial.  23:46-52. 2016
  • First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Executive summary.  23:3-13. 2016
  • Transgenic expression of human CD46: Does it reduce the primate T-cell response to pig endothelial cells?.  22:487-489. 2015
  • Further evidence for sustained systemic inflammation in xenograft recipients (SIXR).  22:399-405. 2015
  • Experimental hepatocyte xenotransplantation - A comprehensive review of the literature.  22:239-248. 2015
  • Pig kidney graft survival in a baboon for 136 days: Longest life-supporting organ graft survival to date.  22:302-309. 2015
  • Characterization of the cellular infiltrate in bioprosthetic heart valves explanted from patients with structural valve deterioration.  22:406-407. 2015
  • Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement pathway-regulatory protein.  22:310-316. 2015
  • Efficient generation of genetically distinct pigs in a single pregnancy using multiplexed single-guide RNA and carbohydrate selection.  22:20-31. 2015
  • Expression of NeuGc on pig heart valves.  22:153-154. 2015
  • Glucose metabolism in pigs expressing human genes under an insulin promoter.  22:70-79. 2015
  • In vitro exposure of pig neonatal isletlike cell clusters to human blood.  22:317-324. 2015
  • Islet xenotransplantation: What is the optimal age of the islet-source pig?.  22:7-19. 2015
  • Pig-to-baboon heterotopic heart transplantation - Exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens.  22:211-220. 2015
  • Reduced human platelet uptake by pig livers deficient in the asialoglycoprotein receptor 1 protein.  22:203-210. 2015
  • Systemic inflammation in xenograft recipients precedes activation of coagulation.  22:32-47. 2015
  • Development of a consensus protocol to quantify primate anti-non-Gal xenoreactive antibodies using pig aortic endothelial cells.  21:555-566. 2014
  • Progress in pig-to-non-human primate transplantation models (1998-2013): A comprehensive review of the literature.  21:397-419. 2014
  • The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of xenocorneal transplantation.  21:420-430. 2014
  • Tribute to Carl-Gustav Groth (1933-2014), first president of the International Xenotransplantation Association.  21:97-98. 2014
  • A milestone in xenotransplantation research.  21:13-15. 2014
  • Are there advantages in the use of specific pathogen-free baboons in pig organ xenotransplantation models?.  21:287-290. 2014
  • Bioprosthetic heart valves of the future.  21:1-10. 2014
  • Corneal blindness and xenotransplantation.  21:99-114. 2014
  • Erythrocytes from GGTA1/CMAH knockout pigs: Implications for xenotransfusion and testing in non-human primates.  21:376-384. 2014
  • Plasma free triiodothyronine (fT3) levels in baboons undergoing pig organ transplantation: Relevance to early recovery of organ function.  21:582-583. 2014
  • Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition.  21:72-83. 2014
  • Role of P-selectin and P-selectin glycoprotein ligand-1 interaction in the induction of tissue factor expression on human platelets after incubation with porcine aortic endothelial cells.  21:16-24. 2014
  • The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options.  21:201-220. 2014
  • Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: A pilot study.  20:429-437. 2013
  • Histopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejection.  20:292-307. 2013
  • N-linked glycan profiling of GGTA1/CMAH knockout pigs identifies new potential carbohydrate xenoantigens.  20:277-291. 2013
  • Toward clinical islet xenotransplantation - Are revisions to the IXA guidelines warranted?.  20:68-74. 2013
  • Commentary: Limitations of the pig-to-non-human primate islet transplantation model.  20:2-4. 2013
  • Double knockout pigs deficient in N-glycolylneuraminic acid and Galactose α-1,3-Galactose reduce the humoral barrier to xenotransplantation.  20:27-35. 2013
  • Comparison of hematologic, biochemical, and coagulation parameters in α1,3-galactosyltransferase gene-knockout pigs, wild-type pigs, and four primate species.  19:342-354. 2012
  • Anti-gal antibodies in α1,3-galactosyltransferase gene-knockout pigs.  19:305-310. 2012
  • Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation.  19:273-285. 2012
  • Human T-cell proliferation in response to thrombin-activated GTKO pig endothelial cells.  19:311-316. 2012
  • Costimulation blockade in pig artery patch xenotransplantation - A simple model to monitor the adaptive immune response in nonhuman primates.  19:221-232. 2012
  • Immortalized porcine liver sinusoidal endothelial cells: An in vitro model of xenotransplantation-induced thrombocytopenia.  19:249-255. 2012
  • Platelet aggregation in humans and nonhuman primates: Relevance to xenotransplantation.  19:233-243. 2012
  • Clinical lung xenotransplantation - What donor genetic modifications may be necessary?.  19:144-158. 2012
  • Identification of human preformed antibody targets in GTKO pigs.  19:92-101. 2012
  • Porcine alanine transaminase after liver allo-and xenotransplantation.  19:52-55. 2012
  • The effect of Gal expression on pig cells on the human T-cell xenoresponse.  19:56-63. 2012
  • Thrombocytopenia after pig-to-baboon liver xenotransplantation: Where do platelets go?.  18:320-327. 2011
  • A record of international meetings on xenotransplantation 1988-2010.  18:229-231. 2011
  • Clinical pig liver xenotransplantation: How far do we have to go?.  18:158-167. 2011
  • Genetically-modified pig mesenchymal stromal cells: Xenoantigenicity and effect on human T-cell xenoresponses.  18:183-195. 2011
  • Multivisceral xenotransplantation-does it have a future?.  17:418-422. 2010
  • An in vitro model of pig liver xenotransplantation-pig complement is associated with reduced lysis of wild-type and genetically modified pig cells.  17:370-378. 2010
  • The immunology of corneal xenotransplantation: A review of the literature.  17:338-349. 2010
  • Outwitting evolution: Honorary Fellowship Lecture.  17:171-180. 2010
  • Insulin secretion and glucose metabolism in alpha 1,3-galactosyltransferase knock-out pigs compared to wild-type pigs.  17:131-139. 2010
  • Investigation of potential carbohydrate antigen targets for human and baboon antibodies.  17:197-206. 2010
  • The potential of genetically-modified pig mesenchymal stromal cells in xenotransplantation.  17:3-5. 2010
  • Monitoring of porcine and baboon cytomegalovirus infection in xenotransplantation.  16:535-536. 2009
  • Pandemic swine flu 2009: Invited commentary.  16:463-465. 2009
  • Production and characterization of transgenic pigs expressing porcine CTLA4-Ig.  16:477-485. 2009
  • Current status of xenotransplantation and prospects for clinical application.  16:263-280. 2009
  • The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 4: Pre-clinical efficacy and complication data required to justify a clinical trial.  16:229-238. 2009
  • The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Executive summary.  16:196-202. 2009
  • Invited commentary.  16:58-60. 2009
  • Identification of αgal as the major target for human anti-pig antibodies.  16:47-49. 2009
  • Islet xenotransplantation: The pig-to-non-human primate model.  15:104-106. 2008
  • Selection of candidates for islet xenotransplantation.  15:102-103. 2008
  • Erratum: Babesia as a complication of immunosuppression following pig-to-baboon heart transplantation (Xenotransplantation (2007) 14,2, (162-165) DOI: 10.1111/j.1399-3089.2007.00375.x).  14:374. 2007
  • Erratum: The potential of statins in xenotransplantation (Xenotransplantation (2007) 14,2, (100-103) DOI: 10.1111/j.1399-3089.2007.00389. x).  14:374. 2007
  • Rapid loss of intraportally transplanted islets: An overview of pathophysiology and preventive strategies.  14:288-297. 2007
  • Acute gastric dilatation after porcine islet transplantation in a cynomolgus monkey - Case history and review of the literature.  14:265-270. 2007
  • The pig-to-primate immune response: Relevance for xenotransplantation.  14:227-235. 2007
  • The potential of statins in xenotransplantation: Commentary.  14:100-103. 2007
  • Babesia as a complication of immunosuppression following pig-to-baboon heart transplantation.  14:162-165. 2007
  • Isolation outcome and functional characteristics of young and adult pig pancreatic islets for transplantation studies.  14:74-82. 2007
  • Rene Kuss's clinical experience with pig kidney transplantation in 1966 [4].  14:93. 2007
  • Extended coagulation profiles of healthy baboons and of baboons rejecting GT-KO pig heart grafts.  13:522-528. 2006
  • Measurement of anti-CD154 monoclonal antibody in primate sera by competitive inhibition ELISA.  13:566-570. 2006
  • Selected physiologic compatibilities and incompatibilities between human and porcine organ systems.  13:488-499. 2006
  • ABO-incompatible allotransplantation as a basis for clinical xenotransplantation.  13:390-399. 2006
  • Antibodies directed to pig non-Gal antigens in naïve and sensitized baboons.  13:400-407. 2006
  • Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans.  13:357-365. 2006
  • PERV methodology.  13:171. 2006
  • Buccal mucosal cell immunohistochemistry: A simple method of determining the ABH phenotype of baboons, monkeys, and pigs.  13:63-68. 2006
  • Journal requirements for manuscripts on clinical trials of xenotransplantation.  13:2. 2006
  • Letter from the Editors.  13:1. 2006
  • Localized myocardial infarction following pig-to-baboon heart transplantation.  12:489-491. 2005
  • Reducing Gal expression on the pig organ - A retrospective review.  12:278-285. 2005
  • Antibody- and complement-independent phagocytotic and cytolytic activities of human macrophages toward porcine cells.  12:181-188. 2005
  • Which patients first? Planning the first clinical trial of xenotransplantation: A case for cardiac bridging.  12:168-172. 2005
  • How strong is the T cell response in the pig-to-primate model?.  12:85-87. 2005
  • Draft reports for public comment from the US Secretary's Advisory Committee on Xenotransplantation..  12:255-257. 2005
  • Early weaning of piglets fails to exclude porcine lymphotropic herpesvirus.  12:59-62. 2005
  • Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons.  11:416-425. 2004
  • Bone marrow transplantation from α1,3-galactosyltransferase gene-knockout pigs in baboons.  11:361-370. 2004
  • Initial experience with the human anti-human CD154 monoclonal antibody, ABI793, in pig-to-baboon xenotransplantation.  11:353-360. 2004
  • Letter to the editor [3].  11:380-381. 2004
  • Letter to the editor [4].  11:382. 2004
  • Pig spleen transplantation induces transient hematopoietic cell chimerism in baboons [2].  11:298-300. 2004
  • Transfusion of pig red blood cells into baboons [1].  11:295-297. 2004
  • Reduction of anti-Galα1,3Gal antibodies by infusion of types 2 and 6 gal trisaccharides conjugated to poly-L-lysine.  11:210-215. 2004
  • Xenotransplantation Manuscripts Now Published OnlineEarly.  11:109. 2004
  • Absence of humoral and cellular alloreactivity in baboons sensitized to pig antigens.  11:27-32. 2004
  • Galα1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus.  11:101-106. 2004
  • In vitro and in vivo investigation of a novel monoclonal antibody to plasma cells (W5 mAb).  11:78-90. 2004
  • Initial investigation of the potential of modified porcine erythrocytes for transfusion in primates.  11:18-26. 2004
  • Relative effects of GAL+ and GALlow/- porcine hematopoietic cells on primate platelet aggregation and endothelial cell activation: Implications for the induction of mixed hematopoietic chimerism in the pig-to-primate model.  11:72-77. 2004
  • Statement on allogeneic and xenogeneic transplantation by Fifty-Seventh World Health Assembly, 22 May 2004..  11:390. 2004
  • Xenotransplantation: Letter from the Editors.  11:1. 2004
  • Pig kidney transplantation in baboons treated intravenously with a bovine serum albumin-Galα1-3Gal conjugate.  10:606-614. 2003
  • An investigation of the effect of thalidomide on anti-gal antibody production in baboons.  10:470-474. 2003
  • Porcine red blood cells as a source of blood transfusion in humans.  10:384-386. 2003
  • Depletion of anti-Gal antibodies by the intravenous infusion of Gal type 2 and 6 glycoconjugates in baboons.  10:357-367. 2003
  • Inhibition of baboon platelet aggregation in vitro and in vivo by the garlic derivative, ajoene.  10:374-379. 2003
  • 6th Congress of the International Xenotransplantation Association.  10:7-9. 2003
  • An exploratory investigation of the effect of arsenic trioxide on anti-Gal antibody production in baboons.  10:80-87. 2003
  • An investigation of the specificity of induced anti-pig antibodies in baboons.  10:88-93. 2003
  • Neurotoxicity of leflunomide in baboons [2].  10:187-188. 2003
  • Promotion of xenogeneic hematopoietic chimerism in rodents by mononuclear phagocyte depletion.  9:402-409. 2002
  • Differential expression of Galα1,3Gal epitopes on fetal and adult porcine hematopoietic cells.  9:297-300. 2002
  • Anti-Galα1-3Gal IgM and IgG antibody levels in sera of humans and old world non-human primates.  9:148-154. 2002
  • Modulation of the in vivo primate anti-Gal response through administration of anti-idiotypic antibodies.  9:106-114. 2002
  • Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a non-myeloablative regimen and CD154 blockade.  9:3-13. 2002
  • Xenotransplantation: Letter from the editor.  8:223. 2001
  • Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody.  8:157-171. 2001
  • Xenotransplantation: Letter from the editor.  8:81. 2001
  • Report: International Xenotransplantation Association.  8:2. 2001
  • Xenotransplantation: Editorial.  8:1. 2001
  • Letter to Editor.  8:80. 2001
  • Inhibition of platelet aggregation in baboons: Therapeutic implications for xenotransplantation.  7:247-257. 2000
  • Plasma perfusion by apheresis through a Gal immunoaffinity column successfully depletes anti-Gal antibody: Experience with 320 aphereses in baboons.  7:181-185. 2000
  • An approach to the control of disease transmission in pig-to-human xenotransplantation.  7:143-155. 2000
  • Venular thrombosis is the key event in the pathogenesis of antibody- mediated cardiac rejection.  7:31-41. 2000
  • Disordered regulation of coagulation and platelet activation in xenotransplantation.  7:166-176. 2000
  • Pig xenogeneic antigen modification with green coffee bean α- galactosidase.  6:238-248. 1999
  • Different responses of human anti-HLA and anti-αgal antibody to long- term intravenous immunoglobulin therapy.  6:181-186. 1999
  • The problem of anti-pig antibodies in pig-to-primate xenografting: Current and novel methods of depletion and/or suppression of production of anti-pig antibodies.  6:157-168. 1999
  • Major carbohydrate epitopes in tissues of domestic and African wild animals of potential interest for xenotransplantation research.  6:79-89. 1999
  • Effect of pig-specific cytokines on mobilization of hematopoietic progenitor cells in pigs and on pig bone marrow engraftment in baboons.  6:17-27. 1999
  • Intravenous synthetic αgal saccharides delay hyperacute rejection following pig-to-baboon heart transplantation.  6:36-42. 1999
  • Lack of variation in αgal expression on lymphocytes in miniature swine of different genotypes.  6:43-51. 1999
  • Comparative histopathology of hepatic allografts and xenografts in the nonhuman primate.  5:197-206. 1998
  • Depletion of anti-Galα1-3Gal antibody in baboons by specific α-Gal immunoaffinity columns.  5:122-131. 1998
  • Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti-αGal antibody in the baboon.  5:274-283. 1998
  • Xenoantigens and xenoantibodies.  5:6-17. 1998
  • Legal implications of xenotransplantation.  4:132-139. 1997
  • Manipulation of the anti-αGal antibody-αGal epitope system in experimental discordant xenotransplantation.  3:102-111. 1996
  • Ethical aspects of xenotransplantation of current importance.  3:264-274. 1996
  • Investigation of the anti-complement agents, FUT-175 and K76COOH, in discordant xenotransplantation.  3:237-245. 1996
  • Ratites (ostrich, emu) as potential heart donors for humans: Immunologic, anatomic, and physiologic considerations.  3:252-259. 1996
  • Detection, immunoabsorption, and inhibition of cytotoxic activity of anti‐αGal antibodies using newly developed substances with synthetic Gal α1–3Gal disaccharide epitopes.  2:98-106. 1995
  • Inhibition of human anti‐αGal IgG by oligosaccharides derived from porcine stomach mucin.  2:279-288. 1995
  • Screening of baboons as potential liver donors for humans.  2:244-252. 1995
  • Variability of anti‐αGal antibodies in human serum and their relation to serum cytotoxicity against pig cells.  1:58-65. 1994